Moneycontrol
HomeNewsBusinessReal EstateCOVID-19 impact on housing launches: Peripheral areas overtake city centres with 58% new supply in FY21

COVID-19 impact on housing launches: Peripheral areas overtake city centres with 58% new supply in FY21

Of around 1.49 lakh units launched in top 7 cities in FY21, 58% were in the city peripheries; in pre-COVID-19 FY19, their share was 51%

June 17, 2021 / 10:28 IST
Story continues below Advertisement

In the post-pandemic world, the city peripherals areas are front and centre on the radars of homebuyers. Supply lost no time in chasing demand and as much as 58% of about 1.49 lakh homes launched in FY21 are in the peripheries of the leading seven cities, says data by ANAROCK.

Many peripheral micro-markets where demand remained muted before the pandemic are now seeing renewed demand and supply. The previous desire to live in city centres - closer to workspaces, children’s school, etc. - has reduced markedly with the advent of WFH and e-schooling options in the post-pandemic world. People now prefer to live in bigger, open and green spaces in peripheries and that too at affordable rates.

Story continues below Advertisement

In FY19, the share of new launches in the peripheral locations was approximately 51% of about 2.29 lakh home launched in these cities. In FY20, more than 2.07 lakh new units hit these markets and the peripheral areas accounted for a 53% share, it said.

Among these cities, Pune saw the most launches in its peripheral areas – 76% of 29,950 units launched in FY21 – led by Mulshi, Pirangut, Daund, Chakan, Chikhali, Kamshet, and Undri, among others.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show